The selection and dose of antibiotic therapy for biofilm-related infections are based on traditional pharmacokinetic studies using planktonic bacteria. The objective of this study was to characterize the time course and spatial activity of human exposure levels of meropenem and tobramycin against Pseudomonas aeruginosa biofilms grown in an in vitro flow-chamber model.
Introduction
Biofilms are structured communities of bacteria enclosed in an extracellular matrix composed of polysaccharides, proteins and extracellular DNA adherent to a surface. 1 Compared with planktonic bacteria, cells in biofilms are more heterogeneous and exhibit differences in metabolism, antibiotic susceptibility and ability to evade the immune system. In humans, biofilms are typically associated with chronic infections but up to 80% of acute infections may also involve biofilm formation. 2, 3 Patients with cystic fibrosis (CF) are uniquely predisposed to biofilm-associated chronic Pseudomonas aeruginosa lung infections, which, once established in the CF lung, are nearly impossible to eradicate with antimicrobial therapy alone.
Pharmacokinetic (PK) and pharmacodynamic (PD) studies are integral for choosing the optimal antimicrobial dose and dosing schedule for maximizing bacterial killing while minimizing development of antimicrobial resistance and adverse drug events. In vitro PD models are used to quantify the effect of single or combination drugs on bacteria. While static in vitro models use fixed antibiotic concentrations on a set inoculum of bacteria, dynamic in vitro PD models have the advantage of mimicking human PK, allowing the characterization of the time course of antibiotic activity. At present, antibiotic susceptibility testing and PD studies utilizing planktonic culture are considered the norm to guide antibiotic selection and dosing yet are known to be poor predictors of treatment outcomes for biofilm infections. 4 Various in vitro model systems have been used to evaluate the activity of antibiotics on biofilms. [5] [6] [7] [8] Most in vitro studies use statically grown biofilms or dynamic models of constant drug V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
concentrations, which may not be physiologically or clinically relevant. The time course and spatial killing of bacteria in biofilms utilizing antibiotic concentrations used to treat human infections are unstudied.
To assess the effect of in vivo antimicrobial drug concentrations on killing and regrowth of bacteria in biofilms, we conducted a combined spatiotemporal study by first simulating human antibiotic concentrations and then quantifying the bacterial biomass over the time course of antibiotic exposure while visualizing the location and extent of killing and regrowth within the biofilm. Intermittent (e.g. bolus) administration of meropenem and tobramycin and combination therapy of meropenem and tobramycin were chosen to correspond to clinical dosing regimens used to treat CF pulmonary infections. We describe the effects of these antibiotic regimens on early and mature P. aeruginosa biofilms.
Materials and methods

Bacterial strain
GFP-tagged P. aeruginosa PAO1 was used. 5 The MICs of meropenem and tobramycin were determined by broth macrodilution and interpreted in accordance with CLSI guidelines. 9 The minimum biofilm inhibitory concentrations (MBICs) were determined using a previously established biofilm susceptibility assay. 10 
Antibiotics and medium
Meropenem for intravenous injection (lot KA662; expiration date, March 2015; AstraZeneca) and tobramycin for intravenous injection (lot 6005971; expiration date, January 2015; Fresenius Kabi USA, LLC) were obtained from the pharmacy of the University of California San Francisco Medical Center. M9 minimal medium (Amresco, Solon, OH, USA) supplemented with 1 mM MgSO 4 , 0.1 mM CaCl 2 , 0.01 mM FeCl 3 and 0.3 mM glucose was used in the flow-chamber experiments. 5 
Antibiotic concentrations
The free-drug concentrations resulting from intermittent (e.g. bolus) administration of meropenem and tobramycin and combination therapy using continuous-infusion meropenem with bolus administration of tobramycin were chosen to correspond to typical human dosage regimens. Concentrationtime profiles were based on previously described PK parameters of meropenem and tobramycin from healthy volunteers and patients with CF.
11, 12 The target meropenem peak concentration (C p ) was computed to be 107.53 mg/L with t1 =2 " 0.893 h. The target tobramycin peak concentration, based on a dose of 10 mg/kg in a 70 kg adult, was 32.79 mg/L with t1 =2 " 2.75 h.
In vitro PD biofilm model
The one-compartment dynamic biofilm PD model system has been previously described. 13 In brief, PAO1 biofilms were cultured in flow chambers and subsequently treated with one or three doses of meropenem or tobramycin (Table 1) . Biofilms were cultured for 24 or 72 h to investigate the effect of maturity on antimicrobial PD. Each flow chamber was inoculated with 250 lL of an overnight culture of PAO1 (OD 600 " 0.05) and left without flow for 1 h, at which time flow was started (20 mL/h) with minimal media via a peristaltic pump (Watson Marlow 205S). Antibiotics were administered after culture for 24 or 72 h. To simulate the human PK of a single dose of meropenem or tobramycin, the medium flask was replaced with an antibiotic flask containing the C p of meropenem or tobramycin. Medium was pumped from a dilution flask to the antibiotic flask and, subsequently, to the flow chambers at a rate calculated to simulate the antibiotic elimination rate constant. To simulate multiple bolus doses of meropenem or tobramycin, the antibiotic bottle was replaced with a fresh bottle of antibiotic at the start of each dosing interval. For the combination study of meropenem plus tobramycin, the dilution flask was replaced with a bottle of meropenem at a concentration of 20 mg/L. Two control channels and three treatment channels were used for each experiment. Each experiment was conducted in duplicate.
Antibiotic concentration determinations
Drug samples were taken via a Luer lock distal to each channel and immediately stored at #80 C until analysis. Meropenem samples were taken at times 0, 0.5, 1, 2, 4, 6 and 8 h. Tobramycin samples were taken at times 0, 0.5, 1, 2, 4, 6, 8 and 24 h. Meropenem was quantified by LC-MS/MS as previously described.
14 Tobramycin was quantified by LC-MS/MS with a calibration range of 50-25000 ng/mL. Quality control samples for meropenem exhibited relative standard deviations (RSDs) ranging from 1.8% to 6.1% and intra-assay mean accuracies ranging from 94.3% to 107% at 150 ng/mL (n " 10), 1500 ng/mL (n " 10), 8000 ng/mL (n " 10) and 100000 ng/mL (n " 16). Quality control samples for tobramycin exhibited RSDs ranging from 2.4% to 5.2% and intra-assay mean accuracies ranging from 96.8% to 109% at 150 ng/mL (n " 5), 1500 ng/mL (n " 9), 20000 ng/mL (n " 9) and 40000 ng/mL (n " 9).
Microscopy and image acquisition
Microscopic observations of bacterial biofilms in the flow chambers were acquired using a Leica TCS SP2 confocal laser scanning microscope (CLSM) equipped with an argon/krypton laser and detectors/filter sets for simultaneous monitoring of GFP (excitation 488 nm, emission 517 nm) representing live cells and propidium iodide (excitation 543 nm, emission 565 nm), which only stains dead cells. Images were obtained using a 40%/1.3 PlanNeofluar oil objective. Each flow-chamber channel was randomly imaged at two locations per timepoint, resulting in six images of the drug channels and four images of the control channels per timepoint. Image locations were randomly selected to provide a broad overview of the effect of antibiotic exposure on overall biomass. Multichannel simulated fluorescence projections and sections through the biofilms were generated using Imaris (Bitplane AG, Switzerland). CLSM images were analysed using COMSTAT. 15 
PK/PD modelling
The mathematical models used to characterize the action of antibiotics on bacterial growth take into account the drug PK, the intrinsic bacterial growth rate and the action of drug on the growth rate (PD). The PK of each antibiotic regimen was simulated in the flow chambers on PAO1 biofilms cultured for 24 or 72 h.
Haagensen et al.
For the PK, we used a linear interpolant of the observed drug concentrations to obtain a continuous function of time (t) that obtains drug concentration, C(t), at an arbitrary time t. The linear interpolant was used to simplify the incorporation of the PK data corresponding to the different modes of administration.
For the bacterial intrinsic growth rate (in absence of drug) we used a Gompertz model. 16 The rate of change for (live) biofilm (B) is given by:
where B 0 is the initial condition (inoculation), k b is the growth rate of the biofilm and B max is the maximum biomass. The growth rate is at its maximum at inoculation when the actual birth rate is at k b log(B max /B 0 ), and approaches zero, i.e. k b log(B max /B max ), when B(t) approaches the maximum growth level. To describe the action of drug on bacterial growth we used standard PD models. 17 In presence of two drugs, C 1 (t), meropenem, C 2 (t), tobramycin, the general model for action of drug is:
The function g(C 1 ,C 2 ,B) represents the action of drug on bacterial growth rate. We also used two alternative models for g(C 1 ,C 2 ,B). In the first we assumed a linear killing action of drug on biofilm:
where k 1 and k 2 are the kill rates for meropenem and tobramycin, respectively. The second adds an interaction term, and takes the form:
where k 12 is the killing rate for the drug interaction. Alternative models for bacterial growth or drug action did not show statistically significant improvements of the model.
PK/PD simulations
Simulations of PD response were based on final parameter estimates for the selected models. Drug elimination rates used in the simulation were 0.767 and 0.252 h #1 for meropenem and tobramycin, respectively. When simulating a bolus dose followed by mono-exponential disposition, the dose was adjusted to achieve an initial concentration of 107.53 mg/L for meropenem and 32.79 mg/L for tobramycin. For the simulated interaction experiment we used the same dosage for tobramycin; for meropenem, we used a constant infusion of 107%0.252 L #1 h #1 lasting 24 h.
Statistical analysis
The parameters B 0 , B max , k b , k 1 and k 2 , and k 12 were estimated from the data using the non-linear minimization program NONMEM7, 18 using the first-order conditional expectation method (FOCE). The compiler used was the public domain GFORTRAN. 19 NONMEM7 minimizes as objective function (OBJ) minus twice the logarithm of the linearized maximum likelihood. To simplify the analysis, we quantify two sources of variability: (i) in the model parameters, due to growth/killing variation across channels (inter-channel variability), assuming that the parameters are log-normally distributed; and (ii) in the observations, due to measurement error (residual variability), assuming normally distributed constant (homoscedastic) error. To determine the statistical significance between competing models, different statistical selection criteria were used that required a minimal decrease of 2-10 points in the OBJ to accept a model with one additional parameter. [20] [21] [22] To compare between models, we used standard regression diagnostic plots.
Results
Static antibiotic susceptibility testing
The MIC of both meropenem and tobramycin was found to be 2 mg/L. The MBIC of both meropenem and tobramycin was found to be 16-fold higher than the MIC (32 mg/L).
Temporal effect of meropenem and tobramycin on P. aeruginosa biofilms Table 1 shows the antibiotic regimens administered in the flow chambers. Single doses of meropenem or tobramycin were administered to 24 h-cultured P. aeruginosa PAO1 biofilms. Multi-dose and combination drug regimens were administered to 72 h-cultured P. aeruginosa PAO1 biofilms. Parameter estimates representing the temporal killing effects of the antibiotic regimens are shown in Table 2 . B max , in the absence of drug, was 39.3 lm . Using a 24 h P. aeruginosa PAO1 biofilm, a single dose of meropenem exhibited more rapid killing (k 1 
). The kill rates for meropenem and tobramycin were approximately 10-fold slower when applied to a 72 h biofilm compared with the kill rates using a 24 h biofilm (k 1 Spatiotemporal pharmacodynamic biofilm modelling
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Simulated plots for each experiment are shown in Figure 1 . Table 3 lists the time and antibiotic concentration associated with biofilm regrowth during each dosing interval. Both meropenem and tobramycin exhibited rapid killing and regrowth with a 24 h biofilm. However, with a 72 h biofilm treated with multiple doses of meropenem, regrowth occurred earlier and at progressively higher drug concentrations with each repeated dose, indicating rapid development of antibiotic tolerance. 23 By the third dose, regrowth Figure 1 . PD simulations of effects of meropenem and tobramycin on P. aeruginosa PAO1 biofilms grown in flow chambers. 24 h biofilms were treated with either a single dose of meropenem or tobramycin at t " 24 h. 72 h biofilms were treated with either three doses of meropenem (at t " 72, 80 and 88 h) or tobramycin (at t " 72, 96 and 120 h) or a combination of meropenem and tobramycin (at t " 72 h) MEM, meropenem; TOB, tobramycin. Table 3 . Time to regrowth, antibiotic concentration and live biomass of 24 and 72 h PAO1 biofilms during treatment with meropenem and tobramycin based on the parameter estimates reported in Table 2 ) or 10-fold faster than either meropenem or tobramycin alone ( Table 2 and Figure 1 ).
Spatial effect of meropenem and tobramycin on P. aeruginosa biofilms
The spatial effect of each antibiotic regimen was evaluated using CLSM images acquired at multiple timepoints throughout each dosing interval. Figure 2 shows the formation of PAO1 biofilm in the absence of antibiotic treatment. Figure 3 shows the effect of a single bolus dose of meropenem (top panels) or tobramycin (bottom panels) on a 24 h PAO1 biofilm. With one dose of meropenem, bacterial killing was rapid, occurring within the first hour of antibiotic exposure. By 8 h (e.g. the end of a typical 8 h dosing interval), biofilm killing was near complete, with a layer of dead cells remaining attached to the substratum surface. Tobramycin exposure resulted in slower killing and a distinct spatial pattern of killing compared with meropenem. While meropenem-killed cells remained attached to the substratum, treatment with tobramycin led to detachment of most cells (live and dead). Few live cells remained attached at 16 and 24 h, with no dead cells remaining. Figure 4 (part I) shows the spatial killing due to three boluses of meropenem on a 72 h biofilm. Panel (a) shows the effects of the first dose of meropenem. Biofilm cell kill was rapid, taking place within the first hour (t " 73 h), and initiating from the top cell layer of microcolonies closest to the biofilm surface and the tops of the mushroom caps. At t " 76 h (4 h into treatment), killing was observed deeper within the mushroom cap, with cells within the mushroom stem remaining viable. With repeated meropenem doses (panels b and c), cells deeper within the biofilm were killed incrementally, reaching the substratum cell layer by the end of the second dose. However, subpopulations in the biofilm remained viable throughout all three doses, as shown in the cut-out sections in panel (c). Figure 4 (part II) shows the spatial killing due to three boluses of tobramycin. Like meropenem, early killing with the first dose appeared to preferentially target the populations at the outer surface of the biofilm and the mushroom caps (panel a). However, with the second and third tobramycin doses (panels b and c), subpopulations on the sides of the mushroom stalk were preferentially killed, leaving the mushroom caps and biofilm surfaces unaffected. The centres of the mushroom caps appeared to collapse inward, forming empty, crater-like areas, which may be indicative of cell dispersal. 24 Robust cell proliferation continued at the tops of the mushroom caps, even with repeated tobramycin doses, accounting for the rebound increase in biomass seen in the temporal modelling. Unlike the tobramycin-treated 24 h biofilm, dead cells remained adherent to the substratum with minimal detachment observed.
The effect of combination meropenem and tobramycin therapy is shown in Figure 4 (part III). The spatial pattern of killing appeared to be a combination of the effect of meropenem and tobramycin alone. The predominant mode of killing was 'top-down'; however, by t " 76 h the formation of hollow spaces in the biofilm appeared similar to that seen with tobramycin monotherapy. By t " 88 h, killing was near complete throughout the biofilm with minimal regrowth.
Discussion
In this study, a simultaneous spatial and temporal approach to PD modelling was performed on P. aeruginosa PAO1 biofilms after treatment with clinical human exposures of meropenem and tobramycin.
13 P. aeruginosa biofilms were difficult to eradicate with the most clinically utilized doses of meropenem and tobramycin used in CF patients. The effectiveness of antimicrobial killing was dependent upon the amount of biomass present and biofilm Spatiotemporal pharmacodynamic biofilm modelling JAC maturation. We observed differences in the spatiotemporal organization of cell death and antibiotic tolerance development within the biofilm that suggest a potential mechanism for the known synergistic effects of b-lactam antibiotics in combination with aminoglycosides on P. aeruginosa.
25-28
Temporally, the rate and extent of biofilm killing and recovery varied between antibiotic classes and maturity of the biofilm. Rapid antibiotic tolerance was observed with both antibiotics, exemplified by the ability of biofilm cells to grow in increasingly higher meropenem and tobramycin concentrations. Tobramycin was less effective at eradicating biofilms compared with meropenem, and the ability of the 72 h tobramycin-treated biofilms to rapidly return to pretreatment biomass by the start of each subsequent antibiotic dose was especially concerning.
Spatially, meropenem and tobramycin displayed different patterns of antimicrobial killing and regrowth, which likely contributed to the differences in the timing of antibiotic tolerance development. The pattern of killing with meropenem treatment was Haagensen et al. similar for early and mature biofilms, taking a top-down approach targeting subpopulations at the periphery of the mushroom first. Subsequent doses allowed killing deeper into the biofilm cap and stem. Both killed and live cells remained adherent to the substratum. In contrast, the spatial selectivity of tobramycin differed by maturity of the biofilm. This phenomenon warrants future investigation and suggests the presence of distinct heterogeneous subpopulations within a mature biofilm that can be distinguished based on their susceptibility to pulse-administered antibiotics.
The observed spatiotemporal selectivity of meropenem and tobramycin is complex and reflects the unique features associated with the physiology of biofilm cells and the pharmacological properties of the antibiotic. During biofilm formation, bacterial cells diversify into physiologically and metabolically distinct populations (dependent on nutrient availability and other environmental cues) with varying degrees of antibiotic tolerance.
5,29-31 P. aeruginosa forms heterogeneous 'mushroom-like' structures when grown in glucose-containing minimal media in flow chambers. After initial surface attachment, the mushroom 'stalks' are composed of non-motile bacteria, while the mushroom 'cap' is predominantly composed of motile bacteria requiring type IV pili and flagella. 29, 30 Antibiotic treatment can eradicate susceptible populations within the biofilm, leaving antibiotic-tolerant populations viable and able to proliferate at higher antibiotic concentrations. The regrowth of tobramycin-tolerant cells at the tops of the mushroom caps is of particular interest. In colistin-treated P. aeruginosa, tolerant cells were seen to migrate to the tops of the microcolonies and proliferate at the top of dead cells. 32 A similar phenomenon may be occurring with tobramycin even though tobramycin exhibits a different mechanism of action and targets different subpopulations of cells within the biofilm compared with colistin.
The distinct effects of the two antibiotic classes could be related to biofilm cell detachment and dispersal, a coordinated process that is thought to occur in response to environmental cues or selfproduced signals. 33, 34 During cell dispersion, motile bacteria are released from the inner portion of the biofilms, leaving behind shell-like, hollow structures with walls consisting of non-motile bacteria, such as those we observed. 33 Detached and dispersed cells are physiologically distinct from both planktonic cells and cells in other stages of biofilm development. 33, 35 Cells within the interior of the biofilm, potentially protected from the effects of tobramycin by peripheral cells, may have adapted to a more antibiotic-tolerant state prior to dispersal.
The detachment and dispersion of the biofilm may have important implications in clinical treatment. Multiple studies have shown that monotherapy with an aminoglycoside for Gramnegative bacteraemia was associated with higher microbiological failure and increased mortality compared with treatment with an appropriate b-lactam. [36] [37] [38] [39] [40] [41] [42] We hypothesize that the increased mortality associated with aminoglycoside monotherapy could be due to the induced detachment of live biofilm cells, which can then spread to other sites within the body.
b-Lactam antibiotics inhibit bacterial cell wall synthesis, while aminoglycosides bind to the 30S ribosomal subunit, interfering with protein synthesis. Both antibiotic classes require metabolically active cells to exert their antimicrobial effect. Microcolonies at the surface of the mushroom cap are more metabolically active, making this area of the biofilm more hospitable to active growth and susceptible to antibiotic treatment. 43, 44 We expected the majority of killing to occur at the tops of the mushroom caps for both meropenem and tobramycin. While this was the predominant pattern of killing for meropenem, this was not the case with tobramycin. Tobramycin targeted the periphery of the mushroom stem, with biofilm regrowth and thus antibiotic tolerance development mainly occurring at the top of the mushroom caps. Additionally, antibiotics exhibit selective penetration through the biofilm due to differences in diffusivity and reactivity of the agent in the biofilm, and dose and duration of exposure. [45] [46] [47] [48] b-Lactams freely penetrate biofilms, while aminoglycosides display lower overall penetration and rate of penetration due to interactions of the positively charged tobramycin with the negatively charged exopolysaccharide alginate. [47] [48] [49] [50] These factors could account for the slower kill rate and shorter duration of killing with tobramycin, particularly in the mature biofilms.
With our biofilm model, it is possible to investigate the spatiotemporal effects of antibiotic exposure that more closely recapitulate clinical regimens used to treat human P. aeruginosa infections. These studies reveal temporally and spatially distinct subpopulations of bacterial cells within the biofilm in response to clinically important antibiotic dosing regimens. Ongoing studies using time-lapse imaging and evaluation of additional biofilm parameters (e.g. biofilm thickness) are needed to further assess the effects of antibiotics on heterogeneous structures within the biofilm and distinguish the mechanisms of antibiotic response and tolerance development. These studies may lead to improved antibiotic therapy directed towards biofilm infections such as CF. 
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